Drug Discovery & DDS– category –
-
GLP-1 Receptor Agonist Mechanism of Action: A Comprehensive Approach to Glycemic Control, Weight Loss, and Metabolic Health
(Document via Google Search) Overview GLP-1 Receptor Agonists (GLP-1 RAs) are a class of drugs that mimic incretin action to manage blood sugar and promote weight loss. They stimulate insulin secretion, suppress glucagon production, and ... -
Molecular Glue Degraders Expand Druggable Proteome in Cancer Research: Simple Structure Boosts CNS Delivery Potential
Facebook USA Overview Molecular glue degraders, small molecules that stabilize interactions between otherwise non-interacting proteins, are expanding the 'druggable' proteome in cancer research through targeted protein degradation. Unlik... -
Scientists Discover POLDIP2 as ‘Molecular Glue’ Controlling Heme, Unlocking Insights for Rare Disease Treatment
YouTube (The Deep Dive Lab) USA Overview Scientists have discovered a novel 'molecular glue' controlling heme production, the essential oxygen-carrying molecule. The mitochondrial protein POLDIP2 utilizes heme as a molecular glue to bind... -
NJ Cancer Care Offers New Hope for Refractory Cancer Patients with Bispecific Antibody Therapy
NJ Cancer Care USA Overview NJ Cancer Care highlights bispecific antibody therapy as a groundbreaking treatment utilizing the patient's immune system to target and destroy cancer cells, offering new hope for those unresponsive to standar... -
Eli Lilly’s Oral GLP-1 Agonist ‘Foundayo (orforglipron)’ Receives FDA Approval for Obesity and Overweight Treatment
Drugs.com USA Overview Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, has received FDA approval for adults with obesity or certain weight-related conditions. This small-molecule, non-peptide GLP-1 receptor... -
FDA Grants Fast Track Designation to Erasca’s Oral Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
OncLive USA Overview Erasca's oral pan-RAS molecular glue, ERAS-0015, has received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma. The drug demonstrated promising initial activity in a Phase 1 study for KRAS G12-muta... -
PROTACs vs. Molecular Glues: Comparing Targeted Protein Degraders for Size and Permeability in Drug Selection
Drug Target Review UK Overview PROTACs and molecular glues represent two distinct strategies for targeted protein degradation, each with unique advantages and challenges. PROTACs are bifunctional molecules that recruit an E3 ligase to a ... -
siRNA Therapy Successfully Switches Off Harmful Genes: FDA-Approved Patisiran and Other Drugs for Hereditary Amyloidosis
Works in Progress Magazine UK Overview siRNA therapy is emerging as a promising treatment to slow or halt disease progression by temporarily silencing specific genes. For conditions like hereditary transthyretin amyloidosis, FDA-approved... -
New Blood-Brain Barrier Penetration Strategies: Peptides and ‘Trojan Horse’ Approaches Revolutionize Brain Drug Delivery
Facebook USA Overview The blood-brain barrier (BBB) blocks approximately 95% of drugs, severely impeding treatment for brain disorders. Researchers are developing novel techniques to bypass this barrier, including 'Trojan horse' approach... -
Northeastern Graduate Research Highlights Limits of AI in Drug Discovery: Human Expertise Remains Crucial for Complex Research
Northeastern University USA Overview Northeastern University graduate students examined claims that AI would completely transform drug discovery, concluding that while useful for simple tasks, AI still generates inaccurate results in com...
